Study title:
A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group, Phase II Study to Assess the Efficacy and Safety of RHINOCORT AQUA® (budesonide) Nasal Spray, 16 mg, 32 mg and 64 mg per day versus Placebo in Pediatric Subjects, Ages 2 5 years old with Allergic Rhinitis.
Type of medicine: Medicines containing chemical active substances
|
Therapeutic area: Respiratory Tract Diseases [C08]
|
Brands: Please see report |
MAH holders: Please see report |
Assessment: |
Active substance: BUDESONIDE |
ATC code: |
Document link:
D5360C00005 Study Synopsis.pdf
|
Document date: 2011-09-30
|
Study number: D5360C00005 |
EudraCT number:
|
Scope of study: Clinical |
Population of study subjects:
|
Preterm newborn Infants
|
Newborn infants
(1 to 27 days)
|
Infants and toddlers
(28 days to 24 months)
|
Children
(2 to 11 years)
|
Adolescents
(12 to 18 years)
|
|
-
|
-
|
Y
|
Y
|
Y
|